Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a New Cell-Based AP-1 Gene Reporter Potency Assay for Anti-Anthrax Toxin Therapeutics.

Toxins·2023
Same author

Interchangeability of the Assays Used to Assess the Activity of Anti-SARS-CoV-2 Monoclonal Antibodies.

Viruses·2023
Same author

Recommendations for Virtual Administration of the PSP Rating Scale.

Movement disorders : official journal of the Movement Disorder Society·2022
Same author

Identification of miRNA-mRNA Pairs in the Alzheimer's Disease Expression Profile and Explore the Effect of miR-26a-5p/PTGS2 on Amyloid-β Induced Neurotoxicity in Alzheimer's Disease Cell Model.

Frontiers in aging neuroscience·2022
Same author

Automated intraoperative central sulcus localization and somatotopic mapping using median nerve stimulation.

Journal of neural engineering·2022
Same author

Neuronavigation-Guided Transcortical-Transventricular Endoport-Assisted Endoscopic Resection for Thalamic Lesions: Preliminary Experience.

World neurosurgery·2022

Related Experiment Video

Updated: Sep 16, 2025

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor
07:45

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor

Published on: June 27, 2011

12.8K

A new STAT3-based potency assay for human G-CSF analog therapeutics.

Tao Xie1, Weiming Ouyang1, Yaqin Zhang1

  • 1Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA.

Journal of Pharmaceutical and Biomedical Analysis
|July 11, 2025
PubMed
Summary

A new reporter cell line offers a more accurate method for assessing the potency of recombinant human granulocyte colony-stimulating factor (rhG-CSF) therapies. This assay overcomes limitations of traditional cell proliferation tests, improving reliability for biosimilar drug development.

Keywords:
BioassayG-CSFG-CSF-RPegfilgrastimPotencySTAT3

More Related Videos

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

9.4K
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

735

Related Experiment Videos

Last Updated: Sep 16, 2025

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor
07:45

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor

Published on: June 27, 2011

12.8K
Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

9.4K
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

735

Area of Science:

  • Biotechnology
  • Pharmacology
  • Cell Biology

Background:

  • Recombinant human granulocyte colony-stimulating factor (rhG-CSF) therapies, including filgrastim and pegfilgrastim, are crucial for managing neutropenia in cancer patients.
  • Current bioassays for rhG-CSF potency rely on murine cell proliferation, which suffers from inter-laboratory variability and interspecies receptor differences.
  • These limitations hinder accurate assessment of rhG-CSF product bioactivity and may not fully reflect in vivo human responses.

Purpose of the Study:

  • To establish a novel reporter cell line for a more specific and reliable rhG-CSF potency bioassay.
  • To develop and qualify a reporter-based assay for pegylated rhG-CSF (PEG-rhG-CSF) products.
  • To provide a platform for developing potency assays for other rhG-CSF therapeutics.

Main Methods:

  • Development of a 293-CSF3R-STAT3Luc reporter cell line expressing the human G-CSF receptor and a STAT3-activated luciferase system.
  • Establishment and qualification of a reporter-based potency bioassay using the developed cell line for PEG-rhG-CSF.
  • Validation of the assay for linearity, accuracy, specificity, precision, and robustness.

Main Results:

  • The 293-CSF3R-STAT3Luc cell line demonstrated selective response to rhG-CSF stimulation.
  • The developed reporter-based potency bioassay was linear and accurate across a 25-200% potency range relative to reference material.
  • The assay exhibited acceptable specificity, precision, and robustness, outperforming traditional proliferation assays.

Conclusions:

  • A novel reporter cell line and associated bioassay provide a more reliable method for determining rhG-CSF potency.
  • This assay platform addresses limitations of existing methods, offering improved accuracy and reduced variability for rhG-CSF biosimilars.
  • The reporter cell assay platform holds potential for broader application in potency testing of rhG-CSF class therapeutics.